These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22959706)

  • 1. EV-077 in vitro inhibits platelet aggregation in type-2 diabetics on aspirin.
    Sakariassen KS; Femia EA; Daray FM; Podda GM; Razzari C; Pugliano M; Errasti AE; Armesto AR; Nowak W; Alberts P; Meyer JP; Sorensen AS; Cattaneo M; Rothlin RP
    Thromb Res; 2012 Nov; 130(5):746-52. PubMed ID: 22959706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of different anticoagulants on multiple electrode platelet aggregometry after clopidogrel and aspirin administration in patients undergoing coronary stent implantation: a comparison between citrate and hirudin.
    Zhang HZ; Yu LH; Kim MH
    Platelets; 2013; 24(5):339-47. PubMed ID: 22774770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homocysteine is a novel risk factor for suboptimal response of blood platelets to acetylsalicylic acid in coronary artery disease: a randomized multicenter study.
    Karolczak K; Kamysz W; Karafova A; Drzewoski J; Watala C
    Pharmacol Res; 2013 Aug; 74():7-22. PubMed ID: 23665469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determinants of reduced antiplatelet effect of aspirin in patients with stable coronary artery disease.
    Larsen SB; Grove EL; Neergaard-Petersen S; Würtz M; Hvas AM; Kristensen SD
    PLoS One; 2015; 10(5):e0126767. PubMed ID: 25993271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease.
    Capodanno D; Patel A; Dharmashankar K; Ferreiro JL; Ueno M; Kodali M; Tomasello SD; Capranzano P; Seecheran N; Darlington A; Tello-Montoliu A; Desai B; Bass TA; Angiolillo DJ
    Circ Cardiovasc Interv; 2011 Apr; 4(2):180-7. PubMed ID: 21386092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease.
    Dillinger JG; Drissa A; Sideris G; Bal dit Sollier C; Voicu S; Manzo Silberman S; Logeart D; Drouet L; Henry P
    Am Heart J; 2012 Oct; 164(4):600-606.e1. PubMed ID: 23067920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of aspirin response by Multiplate whole blood aggregometry and light transmission aggregometry.
    Pedersen SB; Grove EL; Nielsen HL; Mortensen J; Kristensen SD; Hvas AM
    Platelets; 2009 Sep; 20(6):415-20. PubMed ID: 19658002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced antiplatelet effect of aspirin during 24 hours in patients with coronary artery disease and type 2 diabetes.
    Christensen KH; Grove EL; Würtz M; Kristensen SD; Hvas AM
    Platelets; 2015; 26(3):230-5. PubMed ID: 24750015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease.
    Henry P; Vermillet A; Boval B; Guyetand C; Petroni T; Dillinger JG; Sideris G; Bal dit Sollier C; Drouet L
    Thromb Haemost; 2011 Feb; 105(2):336-44. PubMed ID: 21136023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation.
    Rollini F; Tello-Montoliu A; Patel R; Darlington A; Wilson RE; Franchi F; Muñiz-Lozano A; Desai B; Bender N; Sakariassen KS; Angiolillo DJ
    J Thromb Thrombolysis; 2014; 37(2):131-8. PubMed ID: 23943337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood.
    Tóth O; Calatzis A; Penz S; Losonczy H; Siess W
    Thromb Haemost; 2006 Dec; 96(6):781-8. PubMed ID: 17139373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of polymorphism and type II diabetes on aspirin resistance in patients with unstable coronary artery disease.
    Gao F; Wang ZX; Men JL; Ren J; Wei MX
    Chin Med J (Engl); 2011 Jun; 124(11):1731-4. PubMed ID: 21740787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Description of response to aspirin and clopidogrel in outpatients with coronary artery disease using multiple electrode impedance aggregometry.
    Gerotziafas GT; Zarifis J; Bandi A; Mossialos L; Galea V; Tsinopoulos G; Chaari M; Baccouche H; Sassi M; Elalamy I
    Clin Appl Thromb Hemost; 2012 Jul; 18(4):356-63. PubMed ID: 22311629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced blood platelet sensitivity to aspirin in coronary artery disease: are dyslipidaemia and inflammatory states possible factors predisposing to sub-optimal platelet response to aspirin?
    Markuszewski L; Rosiak M; Golanski J; Rysz J; Spychalska M; Watala C
    Basic Clin Pharmacol Toxicol; 2006 May; 98(5):503-9. PubMed ID: 16635110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease.
    Würtz M; Grove EL; Kristensen SD; Hvas AM
    Heart; 2010 Mar; 96(5):368-71. PubMed ID: 19910291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease.
    Grove EL; Hvas AM; Mortensen SB; Larsen SB; Kristensen SD
    J Thromb Haemost; 2011 Jan; 9(1):185-91. PubMed ID: 20955349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doubling the clopidogrel dose in patients with reduced responsiveness to the standard dose is associated with a limited effectiveness as evaluated by impedance aggregometry.
    Stellbaum C; Ayral Y; Morguet A; Schultheiss HP; Rauch U
    Cardiovasc Revasc Med; 2012; 13(3):159-66. PubMed ID: 22503564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications.
    Spectre G; Arnetz L; Östenson CG; Brismar K; Li N; Hjemdahl P
    Thromb Haemost; 2011 Sep; 106(3):491-9. PubMed ID: 21800009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet aggregation is dependent on platelet count in patients with coronary artery disease.
    Würtz M; Hvas AM; Kristensen SD; Grove EL
    Thromb Res; 2012 Jan; 129(1):56-61. PubMed ID: 21917303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration.
    Hedegaard SS; Hvas AM; Grove EL; Refsgaard J; Rocca B; Daví G; Kristensen SD
    Thromb Res; 2009 May; 124(1):96-100. PubMed ID: 19215971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.